Under construction – not a live service
Sign in
Taking people in SwedenPhase 4

Shingles vaccine response in people with inflammatory rheumatic diseases

Tests the Shingrix shingles vaccine in adults with inflammatory rheumatic diseases taking treatments.

Key facts

Who runs it
Region Skane Skanes Universitetssjukhus
Where
Lund, SwedenSee the site
Registry title
Vaccination in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the immunogenicity of herpes-zoster vaccine (Shingrix) and protection against infection (HZ-REUMA)
Status
Recruiting
Phase
Phase 4
People taking part
1 person, planned
Started
17 Dec 2024
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
6 November 2023

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with an inflammatory rheumatic disease. It studies how anti-rheumatic treatments affect the response to the herpes-zoster vaccine (Shingrix).

Age
18 years or older
Sex
All sexes can join
Disease stage
Inflammatory rheumatic disease: rheumatoid arthritis, SLE, spondylarthropathies, psoriatic arthritis, systemic vasculitis or systemic sclerosis

Main reasons for not taking part

  • The record does not list exclusion criteria
  • Healthy volunteers cannot join

Where in Sweden

  • Region Skane Skanes UniversitetssjukhusLund, SwedenTaking people

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Plain-language title
Shingles vaccine response in people with inflammatory rheumatic diseasesGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
6 November 2023